Edited by: Carol Miao, University of Washington and Seattle Children's Research Institute, USA
Advances in Cell and Gene Therapy is an open access journal publishing original, high-quality, peer-reviewed articles which cover basic and clinical research relating to advances in cell, gene, and immune therapies and their use in the treatment of a wide range of diseases, including cancer, genetic and immune diseases, and others.
The topics the journal covers include cell, gene and immune therapies in children and adults with a wide range of disorders, including cancers, genetic and immune diseases, and others. All articles include a section or feature detailing the current and future clinical implications of the research.
Journal Metrics
- 25%Acceptance rate
- 100 days Submission to first decision
As part of Wiley’s Forward Series, this journal offers a streamlined, faster publication experience with a strong emphasis on integrity. Authors receive practical support to maximize the reach and discoverability of their work.
Articles
Serpin B9‐Insensitive Granzyme B Mutant Delivered by Engineered Capsid AAV Vectors Demonstrates Selective Killing of EGFR‐Positive Cancer Cells
- 13 June 2025
Long‐Term Correction of Murine Glycogen Storage Disease Type III by AAV‐Mediated Gene Therapy Using an Immunotolerizing Dual Promoter to Express Bacterial Pullulanase
- 17 April 2025
The Impact of Niacin Administration on Plasma Lipids and Gene Expression in the Vervet Monkey Model (Chlorocebus aethiops)
- 5 February 2025
Silencing of B4Galnt1 Gene Prevents GM2 Accumulation in Tay‐Sachs Cells
- 26 March 2024
Induction of Exocytosis Rescues Lysosomal GM2 Accumulation in Tay‐Sachs Disease
- 19 March 2024
The following is a list of the most cited articles based on citations published in the last three years, according to CrossRef.
TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation
- 24 April 2020
CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models
- 10 July 2018
CD276 as a novel CAR NK‐92 therapeutic target for neuroblastoma
- 19 October 2020
Rapid production of clinical‐grade SARS‐CoV‐2 specific T cells
- 12 July 2020
